Fig. 1From: Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestationsTime to first disease flare before (a) and after (b) tocilizumab initiation. Dotted lines represent 95% CIsBack to article page